Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival

Neuropathology

Volumn 29, Issue 3, 2009, Pages 242-247

  Holmlund, Camilla ^a   Haapasalo, Hannu ^b   Yi, Wei ^a   Raheem, Olayinka ^b   Brännström, Thomas ^a   Bragge, Helena ^b   Henriksson, Roger ^a   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Immunohistochemistry; LRIG proteins; LRIG2; Oligodendroglioma; Patient survival

Indexed keywords

LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN 2; LEUCINE RICH REPEAT KINASE 2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CYTOPLASM; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; OLIGODENDROGLIOMA; PROGNOSIS; YOUNG ADULT;

EID: 65649148276     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2008.00970.x     Document Type: Article

References (32)

1. Louis DN, Ohgaki H, Wiestler OD et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007 114 : 97 109.
2. Di Rocco F, Carroll RS, Zhang J, Black PM. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 1998 42 : 341 346. (Pubitemid 28076794)
3. Reifenberger J, Reifenberger G, Ichimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am J Pathol 1996 149 : 29 35. (Pubitemid 26230975)
4. Ding H, Shannon P, Lau N et al. Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res 2003 63 : 1106 1113. (Pubitemid 36278445)
5. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001 15 : 1913 1925. (Pubitemid 32738621)
6. Paleologos NA, Cairncross JG. Treatment of oligodendroglioma: an update. Neuro-oncol 1999 1 : 61 68.
7. Cairncross G, Macdonald D, Ludwin S et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994 12 : 2013 2021.
8. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998 90 : 1473 1479. (Pubitemid 28482012)
9. Thiessen B, Maguire JA, McNeil K, Huntsman D, Martin MA, Horsman D. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 2003 64 : 271 278. (Pubitemid 37203469)
10. van den Bent MJ, Looijenga LH, Langenberg K et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003 97 : 1276 1284. (Pubitemid 36237315)
11. Andersson U, Guo D, Malmer B et al. Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas. Acta Neuropathol (Berl) 2004 108 : 135 142. (Pubitemid 39136299)
12. Korshunov A, Golanov A, Sycheva R. Immunohistochemical markers for prognosis of oligodendroglial neoplasms. J Neurooncol 2002 58 : 237 253.
13. Miettinen HE, Jarvinen TA, Kellner U et al. High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol 2000 26 : 504 512. (Pubitemid 32049849)
14. Park SH, Suh YL. Expression of cyclin A and topoisomerase IIalpha of oligodendrogliomas is correlated with tumour grade, MIB-1 labelling index and survival. Histopathology 2003 42 : 395 402. (Pubitemid 36459817)
15. Bortolotto S, Chiado-Piat L, Cavalla P et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000 88 : 554 557.
16. Miettinen H, Kononen J, Sallinen P et al. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol 1999 41 : 205 211. (Pubitemid 29209808)
17. Miettinen HE, Paunu N, Rantala I et al. Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. J Neurooncol 2001 55 : 29 37. (Pubitemid 34023623)
18. Gur G, Rubin C, Katz M et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. Embo J 2004 23 : 3270 3281. (Pubitemid 39209151)
19. Laederich MB, Funes-Duran M, Yen L et al. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004 279 : 47050 47056. (Pubitemid 39518360)
20. Shattuck DL, Miller JK, Laederich M et al. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007 27 : 1934 1946. (Pubitemid 46310055)
21. Goldoni S, Iozzo RA, Kay P et al. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007 26 : 368 381. (Pubitemid 46122827)
22. Hedman H, Nilsson J, Guo D, Henriksson R Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 2002 41 : 352 354.
23. Nilsson J, Vallbo C, Guo D et al. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001 284 : 1155 1161. (Pubitemid 32917959)
24. Hedman H, Henriksson R. LRIG inhibitors of growth factor signalling - double-edged swords in human cancer? Eur J Cancer 2007 43 : 676 682. (Pubitemid 46502902)
25. Rubin C, Gur G, Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 2005 15 : 66 71. (Pubitemid 41653969)
26. Sweeney C, Miller JK, Shattuck DL, Carraway KL 3rd. ErbB receptor negative regulatory mechanisms: implications in cancer. J Mammary Gland Biol Neoplasia 2006 11 : 89 99. (Pubitemid 44309192)
27. Karlsson T, Mark EB, Henriksson R, Hedman H. Redistribution of LRIG proteins in psoriasis. J Invest Dermatol 2008 128 : 1192 1195.
28. Guo D, Nilsson J, Haapasalo H et al. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol (Berl) 2006 111 : 238 246.
29. Holmlund C, Nilsson J, Guo D et al. Characterization and tissue-specific expression of human LRIG2. Gene 2004 332 : 35 43. (Pubitemid 38624248)
30. Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003 312 : 65 71. (Pubitemid 36578847)
31. Jarvela S, Parkkila S, Bragge H et al. Carbonic anhydrase IX in oligodendroglial brain tumors. BMC Cancer 2008 8 : 1.
32. Kallioniemi O-P, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 2001 10 : 657 662. (Pubitemid 32331572)